DDInter336 DDInter704
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Celecoxib {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Celecoxib {u} (Compound) binds {v} (Gene) PDPK1
PDPK1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Celecoxib {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Celecoxib {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Celecoxib {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Celecoxib {u} (Compound) binds {v} (Gene) PDPK1
PDPK1 {u} (Gene) interacts with {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Everolimus
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Celecoxib (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Celecoxib (Compound) binds PDPK1 (Gene) and PDPK1 (Gene) is upregulated by Everolimus (Compound)
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Everolimus (Compound)
Celecoxib (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Everolimus (Compound)
Celecoxib (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound)
Celecoxib (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Celecoxib (Compound) binds PDPK1 (Gene) and PDPK1 (Gene) interacts with MTOR (Gene) and MTOR (Gene) is bound by Everolimus (Compound)
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)